LUNG trades 400.0% below Wall Street's consensus target of $10.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes LUNG achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Pulmonx Corporation (LUNG) has a Wall Street consensus price target of $10.00, based on estimates from 9 covering analysts. With the stock currently trading at $2.00, this represents a potential upside of +400.0%. The company has a market capitalization of $84M.
Analyst price targets range from a low of $2.50 to a high of $20.00, representing a 175% spread in expectations. The median target of $9.75 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 1 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, LUNG trades at a trailing P/E of -1.5x. Analysts expect EPS to grow +10.6% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 INSPInspire Medical Systems, Inc. | $2.0B | $69.06 | $60.80 | -12.0% | Hold | 57.9x | 27 |
 NVCRNovocure Ltd | $1.9B | $16.25 | $26.00 | +60.0% | Buy | — | 15 |
 ATRCAtriCure, Inc. | $3.0B | $59.95 | $57.29 | -4.4% | Buy | 560.9x | 19 |
 PRCTPROCEPT BioRobotics Corporation | $1.0B | $18.09 | $22.13 | +22.3% | Buy | — | 16 |
 MMSIMerit Medical Systems, Inc. | $5.2B | $87.07 | $101.88 | +17.0% | Buy | 20.2x | 15 |
 ANGOAngioDynamics, Inc. | $641M | $15.51 | $19.50 | +25.7% | Hold | — | 11 |
 TMDXTransMedics Group, Inc. | $3.0B | $87.00 | $96.86 | +11.3% | Buy | 58.7x | 13 |
 MDTMedtronic plc | $114.7B | $89.30 | $98.00 | +9.7% | Buy | 14.9x | 51 |
 BSXBoston Scientific Corporation | $66.3B | $44.62 | $66.30 | +48.6% | Buy | 13.6x | 44 |
 SYKStryker Corporation | $104.8B | $273.40 | $372.39 | +36.2% | Buy | 18.2x | 52 |
Quick answers to the most common questions about buying LUNG stock.
The consensus Wall Street price target for LUNG is $10, representing 400.0% upside from the current price of $2. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
LUNG has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is mixed, with 4 Hold ratings making up the largest segment. The consensus 12-month price target of $10 implies 400.0% upside from current levels.
LUNG's current price is $2 with a consensus target of $10 (400.0% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $20 for LUNG, while the most conservative target is $2.5. The consensus of $10 represents the median expectation. These targets typically reflect 12-month expectations.
LUNG is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 4 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month LUNG stock forecast based on 9 Wall Street analysts shows a consensus price target of $10, with estimates ranging from $2.5 (bear case) to $20 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on LUNG, with a "Buy" consensus rating and $10 price target (400.0% upside). 4 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
LUNG analyst price targets range from $2.5 to $20, a 175% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $10 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.